Study of Royal Jelly Capsules to Reduce Inflammation and Aging Effects in Adults with Chronic Kidney Disease on Hemodialysis

What this Trial Is About

This research aims to evaluate the effects of royal jelly on inflammation and cellular aging in patients with chronic kidney disease CKD who are undergoing hemodialysis. The study focuses on how bioactive compounds in royal jelly may influence inflammation and premature aging processes seen in these patients. It is a clinical, randomized, longitudinal study with a washout and crossover design to better understand these effects. Participants with CKD on hemodialysis will receive either 500 mg capsules of royal jelly daily or placebo capsules for two months. After this supplementation period, there will be an eight-week washout phase, followed by a crossover where participants switch to the other treatment for another two months. Biological samples such as blood and feces will be collected before and after each study period to analyze various markers related to inflammation, antioxidant capacity, and gut microbiota composition. During the study, researchers will assess inflammatory biomarkers, antioxidant enzyme activity, gene and protein expressions related to cellular aging, and uremic toxins from the intestinal microbiota. Nutritional status and dietary intake will also be monitored. The main outcome is the change in inflammatory biomarkers measured at six weeks. The entire study participation includes supplementation periods, washout, and sample collections to comprehensively evaluate royal jellys effects on CKD patients on hemodialysis.

Effects of Royal Jelly Supplementation in Chronic Kidney Disease